paul Wotton
Chairman
pharmaceutical
Cynata Therapeutics
Australia
Biography
Dr. Wotton joined Cynata’s Board of Directors in June, 2016.  He was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through a take-over by Astellas Pharma, Inc., in a US$379 million all cash transaction. Prior to Ocata, Dr. Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS), since October, 2008. Prior to joining Antares, Dr. Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Earlier in his career he held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton is a member of the board of Vericel Corporation, a US company developing autologous cellular therapies and also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada.    Dr. Wotton received his Ph.D. in pharmaceutical sciences from the University of Nottingham and an MBA from Kingston Business School.  In 2014 he was named New Jersey EY Entrepreneur of the Year in Life Sciences.
Research Interest
pharmaceutical science
